[{"id":"f99a8696-8fa3-4a88-8fbc-fa52c7ef12b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03089203","created_at":"2024-04-26T15:50:57.697Z","updated_at":"2024-07-02T16:35:07.388Z","phase":"Phase 1","brief_title":"CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer","source_id_and_acronym":"NCT03089203","lead_sponsor":"University of Pennsylvania","biomarkers":" TGFB1","pipe":" | ","alterations":" FOLH1 expression","tags":["TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CART-PSMA- TGFβRDN cells"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 03/08/2017","start_date":" 03/08/2017","primary_txt":" Primary completion: 09/08/2038","primary_completion_date":" 09/08/2038","study_txt":" Completion: 12/08/2038","study_completion_date":" 12/08/2038","last_update_posted":"2024-04-26"},{"id":"746925ad-4238-4014-a368-7392430557dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05656573","created_at":"2022-12-19T14:58:50.087Z","updated_at":"2024-07-02T16:35:29.865Z","phase":"Phase 1","brief_title":"CART-PSMA Cells for Advanced Prostate Cancer","source_id_and_acronym":"NCT05656573","lead_sponsor":"Nova Therapeutics LLC","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10","pipe":" | ","alterations":" FOLH1 expression","tags":["IFNG • IL6 • TNFA • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CART-PSMA"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-08"},{"id":"0e2c53e2-5daa-4613-9cf4-4a3a1038b338","acronym":"","url":"https://clinicaltrials.gov/study/NCT03198052","created_at":"2021-01-18T15:46:10.109Z","updated_at":"2024-07-02T16:35:55.664Z","phase":"Phase 1","brief_title":"GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers","source_id_and_acronym":"NCT03198052","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA","pipe":" | ","alterations":" MSLN expression • EGFR positive • GPC3 expression","tags":["EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • EGFR positive • GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-02-14"},{"id":"4af37b5e-53c0-463d-aa29-d4176aa0cac9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04637503","created_at":"2021-01-19T20:37:37.669Z","updated_at":"2024-07-02T16:36:38.465Z","phase":"Phase 1/2","brief_title":"4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma","source_id_and_acronym":"NCT04637503","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 4SCAR-T • GD2, PSMA and CD276 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/18/2020","start_date":" 11/18/2020","primary_txt":" Primary completion: 11/19/2020","primary_completion_date":" 11/19/2020","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2020-11-19"},{"id":"307f73d9-02fe-4164-bff8-b7e3cc8feaa3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04429438","created_at":"2021-01-18T21:20:00.358Z","updated_at":"2024-07-02T16:36:44.235Z","phase":"Phase 1/2","brief_title":"Multi-CAR-T Cells Targeting B Cell Lymphomas","source_id_and_acronym":"NCT04429438","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD19 • CD79B • CD22 • CD70 • ANPEP","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • CD79B • CD22 • CD70 • ANPEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e multi-CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 07/31/2023","primary_completion_date":" 07/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2020-06-12"}]